NASDAQ:NTRA - Natera Stock Price, Forecast & News

Natera trades on the NASDAQ under the ticker symbol "NTRA."

Natera Inc (NASDAQ:NTRA) issued its quarterly earnings results on Wednesday, February, 26th. The medical research company reported ($0.44) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.60) by $0.16. The medical research company earned $83.20 million during the quarter, compared to analysts' expectations of $77.84 million. Natera had a negative net margin of 42.45% and a negative return on equity of 252.79%. View Natera's Earnings History.

Natera issued an update on its FY 2020 After-Hours earnings guidance on Wednesday, February, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $335-350 million, compared to the consensus revenue estimate of $334.88 million.

5 brokerages have issued 1 year target prices for Natera's shares. Their forecasts range from $32.00 to $49.00. On average, they anticipate Natera's stock price to reach $42.80 in the next year. This suggests a possible upside of 21.5% from the stock's current price. View Analyst Price Targets for Natera.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natera in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Natera.

Media coverage about NTRA stock has trended negative recently, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Natera earned a daily sentiment score of -2.0 on InfoTrie's scale. They also assigned media coverage about the medical research company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Natera.

Natera saw a decrease in short interest in February. As of February 14th, there was short interest totalling 3,600,000 shares, a decrease of 9.8% from the January 30th total of 3,990,000 shares. Based on an average trading volume of 691,400 shares, the days-to-cover ratio is currently 5.2 days. Currently, 5.3% of the company's stock are sold short. View Natera's Current Options Chain.

Some companies that are related to Natera include Guardant Health (GH), ELEKTA AB/ADR (EKTAY), InVitae (NVTA), Veracyte (VCYT), RadNet (RDNT), CareDx (CDNA), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Personalis (PSNL), Centogene (CNTG), DermTech (DMTK), Anpac Bio-Medical Science (ANPC), Enzo Biochem (ENZ), Celcuity (CELC) and Psychemedics (PMD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Athabasca Oil (ATH), Chipotle Mexican Grill (CMG), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Transocean (RIG) and Allergan (AGN).

(NTRA) raised $101 million in an initial public offering on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

Natera's stock is owned by a number of of retail and institutional investors. Top institutional investors include Fred Alger Management LLC (4.79%), FMR LLC (4.76%), Jennison Associates LLC (3.27%), State Street Corp (3.21%), Bridger Management LLC (1.62%) and Credit Suisse AG (1.26%). Company insiders that own Natera stock include Claremont Creek Partners Fund, John Steuart, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Robert Alan Schueren and Steven Leonard Chapman. View Institutional Ownership Trends for Natera.

NTRA stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Driehaus Capital Management LLC, UBS Group AG, PNC Financial Services Group Inc., AXA, Bank of New York Mellon Corp, Rafferty Asset Management LLC and Perkins Capital Management Inc.. Company insiders that have sold Natera company stock in the last year include Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Robert Alan Schueren and Steven Leonard Chapman. View Insider Buying and Selling for Natera.

NTRA stock was acquired by a variety of institutional investors in the last quarter, including Bridger Management LLC, State Street Corp, Lord Abbett & CO. LLC, Renaissance Technologies LLC, Columbus Circle Investors, Parkman Healthcare Partners LLC, Madison Asset Management LLC and Credit Suisse AG. View Insider Buying and Selling for Natera.

Shares of NTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NTRA stock can currently be purchased for approximately $35.22.

Natera has a market capitalization of $2.73 billion and generates $257.65 million in revenue each year. The medical research company earns $-128,150,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis. Natera employs 975 workers across the globe.View Additional Information About Natera.

The official website for Natera is http://www.natera.com/.

Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The medical research company can be reached via phone at 650-249-9090 or via email at [email protected]